Editorial Board/Aims & Scope
(Source: Oral Oncology)
Source: Oral Oncology - June 1, 2018 Category: Cancer & Oncology Source Type: research
Obturators versus flaps after maxillary oncological ablation: A systematic review and best evidence synthesis
Maxilla and midface defects caused by ablative surgery involve a high level of psychological and physical trauma in patients [1]. Reconstruction of maxillectomy defects is one of the most difficult challenges for the head and neck reconstructive surgeon [2]. Maxillectomy defects can be treated by prosthetic obturation, autologous tissue reconstruction, or a combination of both. However, selection of the optimal approach is still controversial. (Source: Oral Oncology)
Source: Oral Oncology - May 30, 2018 Category: Cancer & Oncology Authors: Yubin Cao, Changhao Yu, Wei Liu, Cheng Miao, Bo Han, Jianong Yang, Longjiang Li, Chunjie Li Tags: Review Source Type: research
Unravelling the molecular signatures in HNSCC: Is the homogenous paradigm becoming obsolete?
Dear Sirs, (Source: Oral Oncology)
Source: Oral Oncology - May 30, 2018 Category: Cancer & Oncology Authors: Divya Gopinath, Rohit Kunnath Menon Tags: Letter to the editor Source Type: research
Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial
Inhibition of the epidermal growth factor receptor (EGFR) signaling using the monoclonal antibodies (mAbs) cetuximab and panitumumab or tyrosine kinase inhibitors including afatinib and erlotinib are established therapeutic approaches for advanced non-small cell lung and colorectal carcinomas. Intensive studies of hematological and breast cancers have indicated the potential value of whole-transcriptome analysis using high-throughput technologies to gain insights into tumor biology and creation of prognostic and/or predictive models. (Source: Oral Oncology)
Source: Oral Oncology - May 28, 2018 Category: Cancer & Oncology Authors: Marco Siano, Vittoria Espeli, Nicolas Mach, Paolo Bossi, Lisa Licitra, Michele Ghielmini, Milo Frattini, Silvana Canevari, Loris De Cecco Source Type: research
AJCC-8ed nodal staging does not predict outcomes in surgically managed HPV-associated oropharyngeal cancer
The TNM staging system has long been the cornerstone for anatomical classification of cancer progression. Accurate cancer staging is important for clinical decision-making, patient stratification for research and clinical trials, and patients ’ perception of their own disease. Periodic updates to the TNM staging system are required as our understanding of cancer tumorigenesis grows, cancer demographics change, and clinical outcomes improve. (Source: Oral Oncology)
Source: Oral Oncology - May 28, 2018 Category: Cancer & Oncology Authors: Kealan C. Hobelmann, Michael C. Topf, Voichita Bar-Ad, Adam J. Luginbuhl, William M. Keane, Joseph M. Curry, David M. Cognetti Source Type: research
Smoking impact on HPV driven head and neck cancer ’s oncological outcomes?
HPV-driven oropharyngeal cancer (OPC) patients are characterized by a better prognosis than their HPV-negative counterparts with a 5 year mortality rate cut in half [1,2]. However this significant survival advantage is not homogeneous and several studies have suggested that among HPV-positive patients those with a smoking history had worse oncological outcomes and a significantly increased risk of death [2–8]. For instance, Huang et al. reported that the 5-year median overall survival was 89% in patients with stage I-II disease (95% CI 85–93%) and a tobacco consumption ≤20 pack year (PY) versus 64% (95% CI 56–73...
Source: Oral Oncology - May 25, 2018 Category: Cancer & Oncology Authors: Haitham Mirghani, Charlotte Leroy, Younes Chekourry, Odile Casiraghi, Anne Aup érin, Yungan Tao, France Nguyen, Even Caroline, Ingrid Breuskin, Antoine Moya Plana, Dana Hartl, François Janot, Stéphane Temam, Philippe Gorphe, Pierre Blanchard Source Type: research
National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation
Treatment delays in cancer care have been linked to decreased survival and local control, increased patient anxiety, and decreased perception of care [1 –8]. There are a variety of causes of delays, including referral to specialists, treatment planning and scheduling, and breaks during treatment [9]. (Source: Oral Oncology)
Source: Oral Oncology - May 23, 2018 Category: Cancer & Oncology Authors: Elliot Morse, Benjamin Judson, Zain Husain, Barbara Burtness, Wendell Yarbrough, Clarence Sasaki, Shayan Cheraghlou, Saral Mehra Source Type: research
The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis
Human papillomavirus (HPV) is the most common sexually transmitted infection in North America [1,2]. The oncogenic potential of HPV was first described in cervical cancer [3]. More recently, the link between oropharyngeal squamous cell carcinoma (OPSCC) and oral HPV infection was established [4,5]. An estimated 72% of OPSCC cases are associated with HPV in North America [6]. The incidence of OPSCC has been rising rapidly, and has overtaken cervical cancer to become the most common HPV-related cancer in the United States [6,7]. (Source: Oral Oncology)
Source: Oral Oncology - May 23, 2018 Category: Cancer & Oncology Authors: Samantha Tam, Shuangshuang Fu, Li Xu, Kate J. Krause, David R. Lairson, Hongyu Miao, Erich M. Sturgis, Kristina R. Dahlstrom Tags: Review Source Type: research
An assessment of patient burdens from head and neck cancer survivorship care
Head and neck cancers (HNC) are a heterogeneous group of cancers characterized by lesions of the upper aerodigestive tract. In the United States, approximately 63,000 new HNC cases are diagnosed annually, accounting for 3% of adult malignancies [1]. As the population of HNC survivors grows, addressing unmet needs in survivorship care becomes increasingly important [2]. The question of survival is no longer the sole focus; rather, coping with the effects of HNC and its treatment demands attention. (Source: Oral Oncology)
Source: Oral Oncology - May 23, 2018 Category: Cancer & Oncology Authors: Sean T. Massa, Rebecca L. Rohde, Carole Mckinstry, Malia Gresham, Nosayaba Osazuwa-Peters, Gregory M. Ward, Ronald J Walker Source Type: research
The unique and valuable soft tissue free flap in head and neck reconstruction: Lateral arm
This article is a review of a less common but versatile and important flap in the head and neck reconstructive tool box: the lateral arm flap. The lateral arm flap was described by Song and colleagues in 1982 and further defined by Katsaros in 1984 [1,2]. This donor site provides well-vasularized soft tissue that can be utilized to reconstruct a variety of head and neck defects. The lateral arm donor site has several key reconstructive advantages that make it an ideal donor site for many head and neck defects. (Source: Oral Oncology)
Source: Oral Oncology - May 23, 2018 Category: Cancer & Oncology Authors: Stephen Y. Kang, Antoine Eskander, Krupal Patel, Theodoros N. Teknos, Matthew O. Old Source Type: research
Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer
Human papillomavirus (HPV)-driven oropharyngeal cancers (OPC) have a good prognosis, yet 20 –25% of patients will recur within 5 years of treatment and a significant portion will die from their disease[1,2]1. After treatment, physical examination and imaging are the basis of current monitoring strategies. However, these modalities are not ideal as the majority of recurrences are diagno sed at a late stage when the likelihood of cure becomes low. This situation calls for the development of new tools to identify patients at increased risk of relapse. (Source: Oral Oncology)
Source: Oral Oncology - May 23, 2018 Category: Cancer & Oncology Authors: Haitham Mirghani, Krystle A. Lang Kuhs, Tim Waterboer Tags: Review Source Type: research
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma
Cetuximab, a human-murine monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is the only targeted therapy that has shown meaningful clinical activity and is approved for the treatment of head and neck squamous cell carcinoma (HNSCC). In the recurrent/metastatic (R/M) setting, it can be used in first line combined with platinum and 5-fluorouracil, or as single agent after progression on first line platinum-based chemotherapy, leading to an overall response rate (ORR) of 13% and disease control rate of 46% [1]. (Source: Oral Oncology)
Source: Oral Oncology - May 19, 2018 Category: Cancer & Oncology Authors: Renata Ferrarotto, William N. William, Jennifer E. Tseng, Shanthi Marur, Dong M. Shin, Barbara Murphy, Ezra E.W. Cohen, Christopher Y. Thomas, Richard Willey, Jan Cosaert, Nusrat Harun, J. Jack Lee, Ignacio W. Wistuba, Robert I. Haddad, Bonnie S. Glisson Source Type: research
Web-based information on oral dysplasia and precancer of the mouth – Quality and readability
Oral epithelial dysplasia (OED) is a histopathological finding associated with an increased risk of malignant transformation of the oral epithelium [1,2]. The World Health Organisation (WHO) describes dysplasia as an altered epithelium that shows various architectural and cellular changes on the surface epithelial layer as a result of accumulated genetic changes [3]. It is estimated that OED affects 0.25% to 0.5% of populations [4]. Clinically, it can present as white, red, or mixed lesion, categorised under the umbrella of oral potential malignant disorders (OPMD), which precede oral cancers in up to 70% of cases [5]. (Source: Oral Oncology)
Source: Oral Oncology - May 18, 2018 Category: Cancer & Oncology Authors: Abdullah Alsoghier, Richeal Ni Riordain, Stefano Fedele, Stephen Porter Source Type: research
Systemic therapy in non-conventional cancers of the larynx
Laryngeal cancer (LC) is a significantly debilitating disease and one of the most challenging malignancies to treat. LC represents 0.8% of all new cancers in the United States. In 2014, there were an estimated 99 914 people living with LC, with about 13 360 cases diagnosed in 2017 [1]. While most (90 –95%) have conventional squamous cell carcinomas (SCC), the remaining cases are either a variant of SCC or another histology managed differently compared to conventional SCC [2]. Several of these tumor types are more often found in non-laryngeal sites and as a result, treatment in the larynx is of ten modeled after treatment...
Source: Oral Oncology - May 18, 2018 Category: Cancer & Oncology Authors: Elaine Tan, Mayur D. Mody, Nabil F. Saba Tags: Review Source Type: research
Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1
Over the past two decades, an increase in incidence of oropharyngeal squamous cell carcinoma (OPC) has been reported in patients with no history of alcohol and tobacco use. Human papillomavirus type 16 has been identified as the most important etiological agent of this malignancy [1]. Following the standard treatment regimes, patients with HPV-associated tumors have a better clinical outcome than patients with tobacco-related carcinomas; however, standard chemo- and radiotherapy is still associated with considerable morbidity and toxicity in these patients. (Source: Oral Oncology)
Source: Oral Oncology - May 18, 2018 Category: Cancer & Oncology Authors: Kamila Hlad íková, Simona Partlová, Vladimír Koucký, Jan Bouček, Jean-Francois Fonteneau, Michal Zábrodský, Ruth Tachezy, Marek Grega, Radek Špíšek, Anna Fialová Source Type: research
